Advocate for safe and drug-free workplaces and communities through legislative advocacy, education, training and excellence in drug and alcohol testing services
Joined March 2018
- Tweets360
- Following38
- Followers140
- Likes22
NDASA Executive Director, Jo McGuire, has been called to testify at hearings that the Drug Enforcement Administration (DEA) is conducting regarding the proposed rescheduling of marijuana from a Schedule I drug under the Controlled Substances Act (CSA) to a Schedule III substance on Thursday, July 2, and Monday, July 6. NDASA has also selected Patrice M. Kelly of Patrice Kelly Consulting to serve as our co-witness during these historic proceedings. Jo's and Patrice's testimony is pivotal in ensuring that the perspectives and concerns of the workplace drug and alcohol testing community are clearly presented, thoughtfully considered, and made part of the official record.
Last night, Congress took an important step toward protecting our roadways, waterways and skies by ensuring marijuana testing continues for critical public safety positions. For the first time since the advocacy for a safety carve-out began, language was included in a bill to do just that. NDASA applauds the House Appropriations Committee’s leadership, which expressed Congress’s intent to keep DOT testing programs, as they have proven to be a successful deterrent for decades. Transportation safety cannot relax requirements around marijuana impairment.
The work is not done. This requirement needs to become law and NDASA will continue to lead the advocacy to do just that.
NDASA retweeted
You know what would increase research into marijuana?
RESEARCH FUNDING. Not tax breaks to the industry.
NDASA retweeted
"Marijuana is a medicine, which is why we need to label it a medicine, so that we can do research to find out if it has any medical applications."
It's not unlike "We have to pass the bill so that you can find out what's in it."
Under the decisive leadership of @POTUS, this Department of Justice is delivering on his promise to improve American healthcare. This includes:
• Immediately rescheduling FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule IIl
• Ordering a new, expedited hearing with set deadlines, to fully reschedule marijuana
These actions will enable more targeted, rigorous research into marijuana's safety and efficacy, expanding patients' access to treatments and empowering doctors to make better-informed healthcare decisions.
The Trump Administration's rescheduling of certain marijuana products creates confusion regarding drug testing of safety-sensitive employees who operate on the nation’s roadways, in the skies, on waterways, and throughout public transportation systems.#DOT
ndasa.com/2026/04/23/ndasa-c…
Register for NDASA's annual Conference and Trade Show before rates go up! Late registration begins April 27. ndasa.memberclicks.net/index…
JOIN US THIS AFTERNOON as Chuck Marting, of Colorado Mobile Drug Testing LLC. for this session on preventing tampering and ensuring the integrity of your drug tests. Learn more and register at ndasa.com/event/march-webina…
Next month NDASA's expert trainers are heading to the upper Midwest. Don't miss your chance to learn from the best in preparation for DOT Oral Fluid testing and more! Look for details at ndasa.com/event.
Seasoned Substance Abuse Professionals, take your SAP business for DOT mandated drug testing programs to the next level with this intensive training program offered during NDASA's 2024 Conference and Trade Show. Learn more at ndasa.com/2024/02/19/introdu…
As a specimen collector, your priority is protecting the integrity of the test. Join subject-matter expert Chuck Marting as he helps you spot the cheaters. Learn more and register at ndasa.com/event/march-webina…
